Time for a new model in patient accessMig Sleeper, vice president, Global Pricing for Astellas Pharma Europe, explains why we must rethink how value is Share XTime for a new model in patient accesshttps://deep-dive.pharmaphorum.com/magazine/patients-partnerships/astellas-new-model-patient-access/
Astellas reports fourth death in halted gene therapy trialThere has been a fourth patient fatality in Astellas’ clinical trial of its AT132 gene therapy for the Share XAstellas reports fourth death in halted gene therapy trialhttps://pharmaphorum.com/news/astellas-reports-fourth-death-in-halted-gene-therapy-trial/
More trouble for Astellas as AT132 gene therapy trial is halted againAstellas has halted dosing in a study of its AT132 gene therapy for the rare disease X-linked myotubular Share XMore trouble for Astellas as AT132 gene therapy trial is halted againhttps://pharmaphorum.com/news/more-trouble-for-astellas-as-at132-gene-therapy-trial-is-halted-again/
After FDA snub, EMA backs FibroGen, Astellas’ roxadustatThe EU regulator has approved FibroGen and Astellas Evrenzo for adults with anaemia caused by chronic kidney disease Share XAfter FDA snub, EMA backs FibroGen, Astellas’ roxadustathttps://pharmaphorum.com/news/after-fda-snub-ema-backs-fibrogen-astellas-roxadustat/
Shot in the arm for Affinivax as it challenges Pfizer’s PrevnarAlready facing one rival to its blockbuster pneumococcal vaccine Prevnar, Pfizer could have another to contend with, after Share XShot in the arm for Affinivax as it challenges Pfizer’s Prevnarhttps://pharmaphorum.com/news/shot-in-the-arm-for-affinivax-as-it-challenges-pfizers-prevnar/
New Cell & Gene Therapy Collective seeks to boost UK adoptionThe UK has been a global leader in introducing cell and gene therapies that can potentially transform the Share XNew Cell & Gene Therapy Collective seeks to boost UK adoptionhttps://pharmaphorum.com/views-and-analysis/new-cell-gene-therapy-collective-seeks-to-boost-uk-adoption/
Astellas, Seagen seek speedy reviews of Padcev in bladder cancerThe next milestone in Seagen and Astellas’ bid to build their antibody-drug conjugate (ADC) Padcev into a blockbuster Share XAstellas, Seagen seek speedy reviews of Padcev in bladder cancerhttps://pharmaphorum.com/news/astellas-seagen-seek-speedy-reviews-of-padcev-in-bladder-cancer/
Global impact: How regulatory affairs is shaping development of cutting-edge pharma innovationWhen it comes to developing cutting-edge innovations, Astellas aims to be at the forefront. The pharma organisation prides Share XGlobal impact: How regulatory affairs is shaping development of cutting-edge pharma innovationhttps://pharmaphorum.com/views-and-analysis/global-impact-how-regulatory-affairs-is-shaping-development-of-cutting-edge-pharma-innovation/
Astellas/Seagen prepare full US filing of bladder cancer drug PadcevAstellas and Seagen have the data they need for a full licence for their bladder cancer drug Padcev Share XAstellas/Seagen prepare full US filing of bladder cancer drug Padcevhttps://pharmaphorum.com/news/astellas-seagen-to-prepare-for-full-us-filing-of-bladder-cancer-drug-padcev/
